An inducible model for genetic manipulation and fate-tracing of … – Nature.com

The role of mesenchymal cell populations in the development of liver fibrosis has been extensively studied in the last decades15,16,17,18,19, but oftentimes interpretation of the results is limited by the models used.

Both the Lrat- and the PDGFR promoters were shown to label HSCs in the context of liver fibrosis of different etiologies3,7. However, both the previously described LratCre and PDGFR-Cre reporter mice have a constitutively active Cre recombinase, which limits their use. This can result in unspecific activity if the promoter is only temporarily active in the course of cell differentiation, but not specific for the differentiated cell20. Furthermore, the time point of Cre activity can be a concern once a specific deletion results in cell lethality during early development.

Those concerns could be addressed by using a transgenic mouse model with inducible Cre expression. However, no such model that targets mesenchymal cell populations has been published so far. We therefore investigated whether the inducible PDGFR-P2A-CreERT2 mouse11 can be used as a reliable tool to express transgens in mesenchymal cell populations in the liver.

To address this question, we generated a triple transgenic mouse model containing the PDGFR-P2A-CreERT211, a red fluorescent tdTomato Cre reporter21, and a Col1a1-driven GFP22. Our data revealed that tamoxifen-induced activation of PDGFR-P2A-CreERT2 efficiently induced reporter gene expression in pericytes of the liver, which lasted up to one year after activation. Experiments with vehicle-treated mice showed practically no reporter expression, demonstrating no significant leakiness of the PDGFR-P2A-CreERT2 construct which has been observed for other CreER transgenic mice, such as the RipCreER, a beta-cell specific mouse line that can be used to manipulate gene expression in insulin-producing cells of the endocrine pancreas23. PDGFR-P2A-CreERT2 induced reporter expression was tested via immunostaining for markers of different liver resident cell types, in which fluorescent reporter expression only overlapped with desmin, a marker commonly used to stain pericytes in different organs, including HSCs3,24,25,26. Staining for the portal fibroblast marker Thy1.2 revealed overlap with PDGFR-P2A-CreERT2 induced reporter expression, which is in line with previous data showing that fibroblasts and VSMC express Thy1 to a certain extent5. It has been suggested that HSCs and Thy1.2 positive cells are two distinct cell populations13,27, however it cannot be excluded that also some HSCs express Thy15.

Furthermore, PDGFR-P2A-CreERT2 induced reporter expression remained specific for mesenchymal cells even under fibrogenic conditions in the CCl4 toxic liver fibrosis model. Overlap of alpha smooth muscle actin, a common myofibroblast marker, and overlap with endogenous collagen 1a1 driven GFP further confirmed that fibrogenic cells in the liver are PDGFR-P2A-CreERT2 derived. As we achieve a high recombination of PDGFR-P2A-CreERT2 in retinoid positive HSCs of over 90% and a similarly high percentage of pericyte derived myofibroblasts in three different liver fibrosis models, the inducible PDGFR-P2A-CreERT2 model can be used once an inducible Cre mouse model for liver mesenchymal cell populations is required with a similar efficiency as the constitutive PDGFRCre7 or the well accepted LratCre transgenic mouse model3.

However, PDGFRCre as a marker for fibrogenic cells in the liver has some limitations. In recent years, single cell RNA sequencing studies using a Pdgfrb-GFP transgenic mouse have revealed a spatial zonation of HSCs with central-vein-associated HSCs and portal vein-associated HSCs, whereby central-vein-associated HSCs were the dominant collagen-producing cells in CCl4 induced toxic liver injury5. Without other markers, PDGFRCre cannot distinguish between these different HSC populations with distinct functions and the different PDGFR-positive cell populations including fibroblasts, HSCs and VSMC5. Furthermore, another study identified several clusters of fibroblasts in the liver, with some of them (Fib-3 and Fib-4 clusters) expressing low levels of Pdgfrb and thus being underestimated in studies using Pdgfrb as a promoter for Cre recombinases or GFP14. We also performed immunohistochemistry for Slit2, a marker for portal fibroblasts with mesenchymal stem cell features (PMSCs)14. In contrast to this study, we observed Slit2 expression not only restricted to the portal area, but also in the liver parenchmya. Of note, PDGFR-P2A-CreERT2 driven tdTomato expression overlapped with Slit2, both in normal and fibrotic liver indicating that Slit2 might not only be a precursor for PMSCs but also for HSCs. Further studies need to address this finding.

Nevertheless, our data demonstrates that the tamoxifen inducible PDGFR-P2A-CreERT2 mouse model is similarly efficient to the established constitutive LratCre and PDGFR-Cre mouse models and can be applied once an inducible Cre recombinase is required to study liver fibrogenesis.

See more here:
An inducible model for genetic manipulation and fate-tracing of ... - Nature.com

Global Hematological Cancers Therapeutics Market to Reach $122.75 Billion by 2032, Driven by Rising Prevalence – EIN News

The global hematological cancers therapeutics market size was USD 66.77 Billion in 2022 and is expected to reach USD 122.75 Billion in 2032

Although the development of novel treatments is leading to increased demand for hematological cancer therapies, the high cost of medicines, negative effects of therapies, and availability of alternative treatments remain major challenges to the growth of the market. Despite these challenges, rising R&D investments by government entities, commercial businesses, and academic institutions are expected to drive revenue growth.

Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/download-free-sample/1068

Segments Covered in the Report:

The global therapy market is expected to witness significant growth in the coming years. The therapy market is categorized into different types, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The revenue generated by each therapy type is expected to increase from USD billion in 2019 to USD billion by 2032. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells. It is one of the most common cancer treatments and is expected to contribute significantly to the therapy market's revenue. The increasing incidence of cancer worldwide is a major driving factor for the growth of the chemotherapy market.

Targeted therapy is a type of cancer treatment that targets specific genes or proteins that contribute to cancer cell growth. It is expected to witness significant growth in the coming years, owing to its increasing effectiveness in cancer treatment. Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer cells. It is a relatively new type of cancer treatment and is expected to witness significant growth in the coming years, owing to its potential to treat a wide range of cancers. Stem cell transplantation is a type of cancer treatment that involves replacing diseased bone marrow with healthy bone marrow stem cells. It is primarily used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma. The increasing incidence of these types of cancers is expected to contribute significantly to the growth of the stem cell transplantation market.

The therapy market is also categorized based on the indication, including leukemia, lymphoma, and multiple myeloma. The revenue generated by each indication is expected to increase from USD billion in 2019 to USD billion by 2032. Leukemia is a type of blood cancer that affects the bone marrow and blood cells. The increasing incidence of leukemia worldwide is a major driving factor for the growth of the leukemia market. Lymphoma is a type of cancer that affects the lymphatic system. The increasing incidence of lymphoma worldwide is a major driving factor for the growth of the lymphoma market. Multiple myeloma is a type of blood cancer that affects the plasma cells in the bone marrow. The increasing incidence of multiple myeloma worldwide is a major driving factor for the growth of the multiple myeloma market.

The therapy market is also categorized based on the regional outlook, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The revenue generated by each region is expected to increase from USD billion in 2019 to USD billion by 2032.

North America is expected to dominate the therapy market owing to the increasing incidence of cancer and the high cost of cancer treatment in the region. Europe is also expected to witness significant growth owing to the increasing investment in cancer research and development. The Asia Pacific region is expected to witness significant growth owing to the increasing healthcare infrastructure and the rising prevalence of cancer in the region. Latin America and the Middle East and Africa are also expected to witness significant growth owing to the increasing government initiatives and investments in the healthcare sector.

Strategic Development:

Strategic advancements in the healthcare industry include significant developments in various drug treatments for different types of cancers. AbbVie Inc. declared positive outcomes from a Phase 3 clinical trial in September 2021 that assessed the drug, VENCLYXTO (venetoclax), in combination with a Hypomethylating Agent (HMA) to treat newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients or those ineligible for intensive chemotherapy.

AstraZeneca plc announced that its drug, CALQUENCE (acalabrutinib), was granted regulatory approval by the European Commission in May 2021 for the treatment of adults with chronic lymphocytic leukemia (CLL). Additionally, Bristol-Myers Squibb Company stated that its drug, REBLOZYL (luspatercept-aamt), was granted regulatory approval by the European Commission in March 2021 to treat anemia in adults with beta-thalassemia who need regular Red Blood Cell (RBC) transfusions.

Furthermore, in November 2020, GlaxoSmithKline plc partnered with iTeos Therapeutics Inc. to develop and market iTeos's cancer immunotherapy, EOS-448, together with GlaxoSmithKline's hematological cancer therapies.

Access Full Report Description with Research Methodology and Table of Content @ https://www.reportsanddata.com/report-detail/hematological-cancers-therapeutics-market

Competitive Landscape:

The global hematological cancers therapeutics market is highly competitive, with several key players operating in the industry. These major players are AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis International AG, and Pfizer Inc. AbbVie Inc. is a leading player in the global hematological cancers therapeutics market, with a strong portfolio of products, including Imbruvica and Venclexta. Amgen Inc. is another major player in the industry, offering a range of products for the treatment of hematological cancers, including Neulasta, Kyprolis, and Blincyto.

AstraZeneca plc is a multinational pharmaceutical company that offers a range of drugs for the treatment of hematological cancers, including Calquence and Lumoxiti. Bristol-Myers Squibb Company is another key player in the market, offering a portfolio of products for the treatment of hematological cancers, including Opdivo and Empliciti. Celgene Corporation is a biotechnology company that focuses on the discovery, development, and commercialization of therapies for the treatment of cancer and other diseases. Its portfolio of products for the treatment of hematological cancers includes Revlimid and Pomalyst.

Hoffmann-La Roche Ltd. is a multinational healthcare company that offers a range of products for the treatment of hematological cancers, including Rituxan and Gazyva. GlaxoSmithKline plc is another major player in the market, offering a portfolio of products for the treatment of hematological cancers, including Zejula and Arzerra. Johnson & Johnson is a multinational healthcare company that offers a range of products for the treatment of hematological cancers, including Darzalex and Imbruvica. Novartis International AG is another key player in the market, offering a portfolio of products for the treatment of hematological cancers, including Kymriah and Tasigna.

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1068

Pfizer Inc. is a multinational pharmaceutical company that offers a range of products for the treatment of hematological cancers, including Besponsa and Mylotarg. These major players are expected to continue to dominate the global hematological cancers therapeutics market in the coming years, owing to their strong product portfolio and focus on innovation and research and development.

Browse More Reports:

Non Corticosteroid Anti-inflammatory Eye drops Market https://www.reportsanddata.com/report-detail/non-corticosteroid-anti-inflammatory-eyedrops-market

Blood and Organ Bank Market - https://www.reportsanddata.com/report-detail/blood-and-organ-bank-market

Clinical Trial Management System (CTMS) Market - https://www.reportsanddata.com/report-detail/clinical-trial-management-system-ctms-market

Antiglaucoma Eye Drops Market - https://www.reportsanddata.com/report-detail/anti-glaucoma-eyedrops-market

Anti-inflammatory antibiotics Eye Drops Market - https://www.reportsanddata.com/report-detail/anti-inflammatory-antibiotics-eyedrops-market

Nikhil MorankarReports and Data+ 12127101370email us hereVisit us on social media:FacebookTwitterLinkedIn

Go here to see the original:
Global Hematological Cancers Therapeutics Market to Reach $122.75 Billion by 2032, Driven by Rising Prevalence - EIN News

Citius Pharmaceuticals Announces $15 Million Registered Direct … – PR Newswire

CRANFORD, N.J., May 4, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,500,001 shares of its common stock, at a purchase price of $1.20 per share and accompanying warrant in a registered direct offering. The closing of the offering is expected to occur on or about May 8, 2023, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The warrants have an exercise price of $1.50 per share, will be exercisable six months from the date of issuance, and will expire five years from the date of issuance.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting the placement agent fees and other offering expenses payable by the Company. Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.

The securities described above are being offered pursuant to a "shelf" registration statement (File No. 333-255005) filed with the Securities and Exchange Commission (SEC) and declared effective on April 16, 2021. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and be available at the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rdFloor, New York, NY 10022, by calling (646) 975-6996 or emailing [emailprotected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. For more information, please visit http://www.citiuspharma.com.

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price, and includes all statements related to the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering. Factors that could cause actual results to differ materially from those currently anticipated, include, without limitation: risks related to the closing of the offering; market and other conditions; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; our need for substantial additional funds; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; patent and intellectual property matters, our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:Ilanit Allen[emailprotected]908-967-6677 x113

Media Contact:STiR-communicationsGreg Salsburg[emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

The rest is here:
Citius Pharmaceuticals Announces $15 Million Registered Direct ... - PR Newswire

Recombinant proteins market is projected to grow at a CAGR of … – Benzinga

Visiongain has published a new report:Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies, Enzymes (Kinases Enzymes, Metabolic Enzymes, Others), Recombinant Regulatory Protein, Hormones, Virus Antigens, Immune Checkpoint Proteins, Others)), Services), by Application (Biopharmaceutical Production (Biologics, Vaccines, Cell & Gene Therapy, Others), Drug Discovery & Development, Research, Diagnostics, Others)), by Host Cell (Mammalian Systems, Bacterial Cells, Yeast & Fungi, Insect Cells, Others), by End-users (Biopharmaceutical and Biotechnology Companies, CROs, Academic & Research Institutes, Diagnostic Laboratories, Others), AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis.

The recombinant proteins market was valued at US$3,079.9 million in 2023 and is projected to grow at a CAGR of 11.14% during the forecast period 2023-2033.

The field of biologics within biotechnology has been recognised to be rapidly growing. Diabetes, autoimmune diseases, and cancer therapies account for more than 60% of the biologics industry. As a result, the cost is exorbitant and growing on a regular basis. According to the World Health Organisation (WHO), these high prices impede healthcare systems from providing affordable, universal access to such treatments. This creates a slew of opportunities for generic drugmakers to create biosimilar copies of original biologics whose patents have lapsed. As a result, generic medication manufacturers are continuously on the lookout for biologics with expiring labels. There will be 230 medicinal patents expiring between 2021 and 2025. PERJETA (Pertuzumab), VYROLOGIX (Leronlimab), and STELARA (Ustekinumab) are just a handful of the biologics that will be phased out in 2023. Biologics already account for half of the cancer pharmaceutical business, according to the Centre for Biosimilars, but their high price is a barrier to access. By 2023, around 20 oncology biologics' patents will have expired, potentially resulting in more biosimilars being utilised in cancer therapy and lower overall prices.

Download Exclusive Sample of Report

Recombinant Proteins Market Report 2023-2033

How has COVID-19 had a Significant Impact on the Recombinant Proteins Market?

The growth of the recombinant protein market was impacted by the COVID-19 pandemic. The advent of COVID-19 has led to a surge in the need for therapeutic and vaccination interventions to counteract its effects. Numerous market participants and public institutions have redirected their attention towards research and development endeavours aimed at addressing COVID-19, with recombinant proteins serving as a crucial component in these initiatives. An article published in the JCLA journal in May of 2022 details how researchers and scientists focused their efforts on recombinant proteins as a means of developing a COVID-19 vaccine. The outbreak of COVID-19 has resulted in an increase in the need for pharmaceuticals based on recombinant proteins. The present circumstances suggest that the studied market is likely to experience substantial growth during the projected timeframe, owing to the widespread occurrence of chronic ailments and coexisting infectious diseases, as well as the effectiveness of recombinant protein-based medication in addressing them.

How will this Report Benefit you?

Visiongain's 358-page report provides 146 tables and 248 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the recombinant proteins market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Recombinant Proteins. Get financial analysis of the overall market and different segments including product & services, application, cell source, and end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing recombinant proteins market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Growing Demand for Vaccine Production

Recombinant proteins are required for the development and production of vaccines. The rapid development of the COVID-19 vaccine, as well as the amount of immunisation demand, is unprecedented in modern medicine. To accommodate this demand, stakeholders have had to rethink their manufacturing methods, make large investments, repurpose existing facilities, and develop sophisticated supply networks. The R&D reaction to COVID-19 has been spectacular. This required a far faster ramp-up of manufacturing than is customary in pharmaceutical development, a difficulty exacerbated by the global nature of vaccine demand.

Emerging Economies and Prioritisation of R&D to Boost Industry Growth

Some of the most rapidly rising economies in the pharmaceutical sector are Brazil, Russia, India, China, South Africa, Mexico, South Korea, Indonesia, and Turkey. In five years, pharmaceutical sales in these countries more than doubled, obtaining a market share of roughly 20% in the worldwide pharma industry. Furthermore, firms are dealing with flattening growth in developed nations, patent expiration, which leads to increased sales of less expensive generic drugs, and strict regulations enforced in mature markets.

Download Exclusive Sample of Report

Recombinant Proteins Market Report 2023-2033

Where are the Market Opportunities?

Rising Significance of Genomics and Proteomics

Proteins perform critical roles in biological systems. A better knowledge of illnesses, health, and, by extension, health outcomes is increasingly seen as a difficult, but necessary, precondition. The recent spread of genome sequencing, powered by a steep decline in sequencing costs, has propelled the rapid rise in the identification of possible genetic targets and associated protein biomarkers for sickness diagnosis and more personalised therapies. To capitalise on this market potential in protein research, the recombinant protein market is seeing high rates of innovation and capital investment in support of several innovative solutions to uncover and analyse protein biomarkers.

Competitive Landscape

The major players operating in the recombinant proteins market are Abcam Plc; Abnova Corporation; Avantor Inc.; Bio-Rad Laboratories, Inc.; Bio-Techne; Enzo Biochem Inc.; GenScript; Merck KGaA; PerkinElmer, Inc; Proteintech Group, Inc.; RayBiotech Life, Inc.; Sino Biological Inc.; STEMCELL Technologies; and Thermo Fisher Scientific Inc. These market's top players have pursued a variety of strategies, including M&A, R&D investment, collaborations, partnerships, regional company development, and new product launches.

Recent Developments

To access the data contained in this document please emailoliver.davison@visiongain.com

To find more Visiongain research reports on thePharmasector, click on the following links:

Do you have any custom requirements we can help you with?Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:oliver.davison@visiongain.com

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds ofmarket research reportswhich it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicatedmarket research reportsoffer a bespoke piece of market intelligence customised to your very own business needs.

Contact:

Oliver DavisonVisiongain Reports LimitedTelephone: +44 (0) 20 7336 6100Email:oliver.davison@visiongain.comWeb:www.visiongain.com

Follow this link:
Recombinant proteins market is projected to grow at a CAGR of ... - Benzinga

HKUs innovative research novelties excel at – EurekAlert

image:Artificial Intelligence MGF Network for Anomalies Detection, developed by Dr Wilton Fok's team, wins two special grand prizes Invention & Innovation CAI Award (China Delegation) and Prize of the Delegation of Malaysia, and a gold medal view more

Credit: The University of Hong Kong

The University of Hong Kong (HKU) triumphed at the 48th International Exhibition of Inventions of Geneva, winning a total of 19 awards, including two special grand prizesInvention & Innovation CAI Award (China Delegation), andPrize of the Delegation of Malaysia.The results were announced yesterday (April 28).

Research teams from Faculty of Architecture, Faculty of Engineering, Faculty of Science,LKS Faculty of Medicine, and two HKU Inno Laboratories, established under the Hong Kong Government's InnoHK programme,garnered two special grand prizes, oneGold Medal with the Congratulations of the Jury, sixGold Medals, sixSilver Medals and fourBronze Medals with their innovations in the event.

TheArtificial Intelligence MGF Network for Anomalies Detection,developed byDr Wilton Fok's team from the Department of Electrical and Electronic Engineering, was winner of the two grand prizes and a gold medal. The system usesAI to analyse in real time human posture and movements in a video to identify anomaly scenarios such as abuse, drowning, and criminal behaviour.

TheProgrammable Cell Niche Engineering Platform,developed byProfessor Barbara Chan's team from the Department of Mechanical Engineering, wonaGold Medal with the Congratulations of the Jury. The system ensures proper cellular functions and results that can enable predictable clinical studies by mimicingthe biological environment for cells.

HKU has showcased this year a total of 17 research inventions that provide solutions to pressing human problems, spanning diverse areas such as biomedicine, vaccine development, artificial intelligence, and aging. Notably, the Advanced Biomedical Instrumentation Centre and the Centre for Virology, Vaccinology and Therapeutics, established by HKU in 2021 under the Hong Kong Government's InnoHK program, have demonstrated exceptional ability in successfully translating their biomedical research achievements into practical applications within a relatively short timeframe. Each have two research inventions selected, including an aptasensor for sepsis diagnosis, a capillary microfluidic platform for point-of-care testing, an interferon-integrated coronavirus vaccine, and NanoComplex vaccine technology.

HKU takes immense pride in the recognition our researchers have received for their innovative research efforts. We are also dedicated to facilitating the transfer of our research findings into tangible applications in the market. Through the powerful synergies generated from our collaborations with global research and industry partners, we strive to facilitate the emergence of pioneering innovations and their transformation into products that improve the well-being of humanity, said Professor Max Shen, Vice-President and Pro-Vice-Chancellor (Research).

Renowned as one of the most distinguished innovation exhibitions in the world, the International Exhibition of Inventions of Geneva (IEIG) is an extraordinary annual global event devoted exclusively to inventions and innovations.

Since first participating in the event in 2018, HKU has received a total of 60 awards including 4 prestigious Gold Medals with Congratulations of the Jury and 21 other gold medals.

HKUs award-winning inventions in 2023:

INVENTION & INNOVATION CAI AWARD (China Delegation) & PRIZE OF THE DELEGATION OF MALAYSIA & GOLD MEDAL

Artificial Intelligence MGF Network for Anomalies DetectionThe invention can be deployed in children's centres, swimming pools, public transport and exhibition centres to detect abnormal behaviours and situations for public safety and security. Using AI to detect human skeletons in a video and analyse their posture and movements, it is able to capture the context information in a long video and address specific portions for detecting multiple anomaly scenarios in real time such as abuse, drowning, terrorist attacks, traffic accidents, fighting and criminal behaviour, more accurately and efficiently.

The invention was developed by the research team of Dr Wilton Fok from the Department of Electrical and Electronic Engineering, The University of Hong Kong.

GOLD MEDALS WITH CONGRATULATIONS OF THE JURY

Programmable Cell Niche Engineering PlatformOne of the reasons many drugs that work in the lab do not work as expected in the clinical trial stage is that scientists grow cells on flat and rigid culture dishes for drug research, which are not biomimetic -- leading to cell responses in lab testing that do not represent what would happen in native tissues of human bodies. The Programmable Cell Niche Engineering Platform mimics the biological environment for cells, which in turn ensures proper cellular functions and results that can enable predictable clinical studies. The multifactorial biochips invented identify the ideal niche for different cell types, equipping scientists with a comprehensive library of individual niche factors to develop optimal culture environments for different types of cells of specialised applications.

The platform was developed by Professor Barbara Chan and her team from the Department of Mechanical Engineering, Biomedical Engineering Programme, The University of Hong Kong.

GOLD MEDALS

1. Respiratory OrganoidsBiomedical research mainly relies on cell lines and animal models for experimentation, which has limited physiological relevance to human biology and pathology. Under this project, a complete respiratory organoid culture system has been the first of its kind to efficiently reconstruct and reproducibly expand the entire human respiratory epithelium in culture plates. All the differentiated respiratory organoids, including nasal, airway and alveolar organoids, adequately mimic the multicellular composition of native respiratory epithelium and phenocopy the functionality. Superior to most existing in vitro models, these organoids represent universal tools with biological relevance for diverse biomedical and pharmaceutical applications, including disease modeling, development of therapeutics, toxicological evaluation and personalised medicine.

The project was originated by Dr Jie Zhou, Dr Man Chun Chiu, Dr Cun Li and Professor Kwok Yung Yuen from the Department of Microbiology, The University of Hong Kong.

2. Bismuth-based Cocktail Therapy for CoronavirusThere is an urgent need for safe and effective therapeutic options for COVID-19, with the SARS-CoV-2 variants associated with enhanced transmissibility, reduced vaccine-induced protection and emerging drug resistance. Under this project, the orally administrated bismuth drug colloidal bismuth subcitrate together with N-acetyl cysteine has been found to be a broad-spectrum anti-coronavirus cocktail therapy against multiple SARS-CoV-2 variants and different coronaviruses. Mixing two US Food and Drug Administration (FDA) approved over counter drugs, 1 molar equivalent of colloidal bismuth subcitrate and 3 molar equivalents of a mucoactive drug N-acetyl cysteine, is a safe and highly potent therapy through oral administration and 10 times more selective in killing the virus than the first FDA approved drug. This therapy is now in phase II/III clinical trial in Hong Kong, with a phase III trial underway in China.

The invention was developed by Professor Sun Hongzhe, Professor Yuen Kwok-yung, Dr Yuan Shuofeng, Dr Wang RunMing, Dr Li Hongyan, Dr Jasper Chan Fuk-Woo, Dr Cheng Tianfan, Mrs Wang SuYu, and Mr Chan Chun Lung of The University of Hong Kong.

3. PERfECT Wearables for Digital HealthEndorsed by over 100 leading scientists worldwide on social media, "HKU PERfECT" is the first wearable platform combining the distinctive features of being highly sensitive, energy efficient, lightweight and ultracompact, enabling decentralised medical technologies for remote and personalised healthcare to cope with an aging population, quarantine and the shortage of medical instrumentation. Compared to current wearable devices that can only measure vital signals (e.g. heart rate, breathing rate, blood pressure, etc.), PERfECT is able to detect molecular indicators in body fluids, which are more informative for fatal/chronic disease screening and monitoring.

The invention was developed by the WISE Research Group from The University of Hong Kong and SESIC LIMITED.

4. Method of Developing a Peptide-based Vaccine Conjugated with 1V209This invention describes the development of a method to conjugate 1V209, a toll-like receptor 7 (TLR7) agonist, to antigens to induce antigen-specific responses. Past synthetic peptide vaccines must be used together with vaccine adjuvants to stimulate T cells against specific antigens to treat cancer, but a simple mixture of antigens and adjuvants can hardly induce enough specific immune responses. To address this issue, we designed bioinspired nanoparticles mimicking the structure of the virus to enhance the antigen-specific immune response. Through safer and greener methods, it used the TLR7 agonist 1V209 to generate peptide-drug conjugates and form a self-adjuvating vaccine to deliver antigens and adjuvants at the same time, inducing a stronger T cell response with improved stability and successful suppression of tumour growth.

The invention was developed by Professor Jiandong Huang and Dr Yefan Hu from the School of Biomedical Sciences, The University of Hong Kong.

5. DipChip Capillary Microfluidic Platform for Point-of-care DiagnosticsDipChip is an automated capillary microfluidic-based point-of-care (POC) microsystem allowing rapid and portable detection of various high-impact and mortality diseases. It is designed and fabricated using state-of-the-art molecular biology and microfluidic technologies, utilising capillary pressure and surface-activating treatments that allow laboratory-level analytics to be conducted in an accessible manner. This microsystem paves the way for a versatile array of clinical and academic applications that require multiple conjugations and washings. End users of DipChip include clinics, hospitals, homes and assisted living healthcare facilities, democratising access to adequate clinical care, and saving precious lives of patients in need.

The platform was developed by Professor Anderson Shum, Dr. Hassan Sammer Ul and Mr. Nicky Lee from Department of Mechanical Engineering and Advanced Biomedical Instrumentation Centre.

SILVER MEDALS

1. Smart Address Plates for Pedestrian Indoor Navigation and Location-Based Services and ManagementTraditionally, pedestrian navigation uses Location Positioning System (LPS) with trilateration to find the users position, which have very high positioning error for outdoor GPS and indoor positioning. This new solution adopts a cost-effective innovative Location Confirmation System (LCS) to accurately locate and guide the user to the destination by using Smart Address Plates (SAP) that transmit stored geographic coordinates with innovative 3D Smart Address (SA) codes to the users even without WiFi or telephone signals. This SAP system can help to find shops/ offices/ restaurants/ car parking spaces inside a multi-storey building accurately while providing location-based services and management for precise target marketing. It is highly scalable, connecting shops/rooms on a floor to a building, then to a district and to the whole city through a Smart Address Plate Management System (SAP-MS).

The Smart Address Plates and Location Confirmation System were developed by Professor Anthony Yeh, Dr Zhong Teng and Dr Run Shi from the Department of Urban Planning and Design, The University of Hong Kong.

2. A Novel Stem Cell-based Platform for Antiviral Discovery, Vaccine and Healthy Natural ProductsThere is an urgent need for the vaccine industry to establish a new type of human cell model for anti-virus drug development in order to enhance sensitivity and efficiency. The human Expanded Potential Stem Cells (hEPSCs) developed under this project help generate trophoblast stem cells (TSCs) and syncytiotrophoblasts (STBs), which express high levels of SARS-CoV-2 host factors and are highly susceptible to the viral infection. Remarkably, the infected eSTBs are 1,000 times more sensitive to antiviral drugs, making the TSC-STB platform a more ideal human cell source for viral production and performing antiviral discovery, including SARS-CoV-2, MERS, their variants, and the FDA approved anti-virus drugs and natural products.

The platform was developed by Professor Pengtao Liu from the Li Ka Shing Faculty of Medicine, and Dr Degong Ruan and Professor Fang Liu from the Centre for Translational Stem Cell Biology, The University of Hong Kong.

3. Ultra-thin Flexible Robotic Instruments for Endoluminal SurgeryUnder this project, a robotic system with highly miniaturised and flexible instruments has been developed to address challenges in the endoluminal treatment of early-stage gastrointestinal and urinary tract cancers. In current practice, there is a steep learning curve for resecting tumours in their entirety due to a lack of instrument dexterity and poor tissue retraction. The developed system provides two robotic instruments as small as 2.5 mm with 5 degrees of freedom each, enabling enhanced endoluminal surgery with conventional rigid and flexible endoscopes. Overall, the system will help to flatten the learning curve so that more clinicians can provide patients with effective early-stage care.

The system was developed by the research team of Dr Ka-Wai Kwok from the Department of Mechanical Engineering, The University of Hong Kong.

4. Automatic Alignment of MicroparticlesThis groundbreaking chip-size invention revolutionises the way to align micro-particles in liquids. Using a microchannel with specifically arranged roadblocks that effortlessly guides disordered particles into an ultrafast-flowing chain, it provides outstanding performance at a low cost. As compact as a credit card and priced at less than USD10, each device can align up to one million particles per minute with precision down to 0.001 mm. This game-changer bypasses the limitations of current methods, thereby enhancing the efficiency of applications that involve microparticle analysis and processing, particularly blood cell screening and water filtration.

The invention was developed by Professor Kevin Tsia and Dr Kelvin Lee from the Department of Electrical and Electronic Engineering, The University of Hong Kong.

5. Interferon-integrated coronavirus vaccine: a next-generation universal live vaccine protects against pan beta-coronavirus infectionIn the wake of the COVID-19 pandemic, it is imperative to develop a next-generation coronavirus vaccine that can offer protection against current and potential future beta-coronavirus infections. However, there are several technical hurdles that must be overcome in order to create an ideal vaccine that has three key properties: 1) universal protection against a broad range of beta-coronaviruses, 2) enhanced mucosal T cell immunity, and 3) activated innate anti-viral mechanisms to ensure safety. The team has developed an innovative immunological design and genetic engineering technology that has resulted in the creation of a universal beta-coronavirus mucosal vaccine and a streamlined production pipeline. Preclinical studies in two animal models have demonstrated the efficacy of the vaccine in terms of the three key properties.

The technology was developed by Dr KH Kok and the team from the Department of Microbiology of The University of Hong Kong and the Centre for Virology, Vaccinology and Therapeutics.

6.NanoComplexNanoComplex is a next-generation vaccine technology designed for nasal use and carries the potential to target all kinds of viruses. Viruses have proteins as antigens and nucleic acids as genomes, and both are critical components to alert our immune system and generate strong protection. The NanoComplex technology takes full advantage of these components, combines viral proteins and nucleic acids with innovative methods, and creates a nano-sized complex that can be used as a nasal vaccine. Since all viruses have the same components, the NanoComplex can switch its internals for different viruses, and therefore can potentially defend against all known viruses.

The technology was developed by a research team lead by Dr Kin Hang Kok from the Department of Microbiology of The University of Hong Kong, and the Centre for Virology, Vaccinology and Therapeutics.

BRONZE MEDALS

1. Remote e-Inspection System for the Manufacturing and Delivery of Offsite Modular ConstructionThis e-Inspection System is a Modular Construction Supply Chain Quality Assurance system that includes i-Core (an loT device attached to each MC module to monitor the position, humidity, temperature and collision data), e-InStar (an App for uploading the checking result of each production step in a remote factory to the block chain), e-TranStar (an App for monitoring the location and condition of the MC module in the transport process) and a blockchain-based backend. Designed for offsite modular construction use to help solve housing problems, it reduces resources required for supervision and paperwork while ensuring tamper-proof data, helping overcome the current difficulties in monitoring the quality of production and transportation from remote sites. The system has been piloted in an HKU project in Hong Kong with two 17-storey buildings using 952 MiC modules.

The system was developed by Prof Wilson Lu, Director of the iLab of the Faculty of Architecture, together with Professor Anthony Yeh, Chair Professor of the Department of Urban Planning and Design, and Mr KL Tam, Former Director of the Estates Office of The University of Hong Kong.

2. On-site Fertilizer Production for Perpetual FarmingThe EC Flow device developed under this project is an energy-neutral system that fully integrates with solar panels and battery storage systems to detect and remove numerous toxic residual nitrates and nitrites (NOx) in soil using renewable energy. It can further upcycle NOx and feed fertilizer back into urban farming sites, achieving waste remediation, pollution mitigation and resource recovery to reach nitrogen neutrality. This solution can be applied to plantation areas of any scale and type, including farms, lawns, roof gardens and balconies. The goals are lowering toxin levels in municipal waste and alleviating ecological strains on urban sewage systems, ultimately improving the urban municipal discharge situation and local marine environment.

The device was innovated by Dr Edmund Tse, Wanying Wang from the Department of Chemistry, The University of Hong Kong, and commercialised with the help of Yip Jackson Ho So.

3. Smart Elderly WalkerThis is a smart and handy device pairing advanced Artificial Intelligence with a home-friendly design, helping the elderly stay healthy, active and independent while making their lives easier and more secure. It brings together several advanced features, including a stable mechanical structure with smooth omnidirectional mobility, dual-mode actuation and control for simultaneous walking/standing support and fall prevention/recovery, soft robotic handles and privacy-friendly sensors for event detection and control and fall detection, as well as specialised sound-source localisation to locate the user quickly and effectively, providing enhanced safety protection and superior walking assistance for older adults.

The device was developed by the research team of Professor Chuan Wu, Dr Hao Luo, Dr Zhao Chongyu and Dr Wen Rongwei from the Department of Computer Science of The University of Hong Kong; and Professor Wang Zheng from the Department of Mechanical and Energy Engineering of The Southern University of Science and Technology in Shenzhen.

4. Aptasensor for Sepsis DiagnosticDiagnosing sepsis in a timely manner to ensure optimal patient survival with prompt treatment remains a major challenge. This invention utilises a novel DNA-based biosensor that integrates aptamers into a point-of-care platform to advance sepsis diagnosis. Aptamers recognise biomarkers by specifically binding to unique structures on their surface. Unlike antibody-based tools, aptamers provide multiple advantages in terms of stability, production cost, reproducibility and flexibility that can readily be integrated into various platforms, such as electrochemical platforms (quantitative device) and/or colorimetric assays (rapid test). The aptasensor provides a quick and highly sensitive solution for sepsis detection that can help revolutionise point-of-care sepsis detection.

The invention was developed by Dr. Louisa Hoi-Ying Lo, Dr. William Whitehouse, supervised by Professor Julian Tanner, from the Advanced Biomedical Instrumentation Centre.

The Universitys participation in this years competition was coordinated by the Technology Transfer Office of HKU.

For details about the International Exhibition of Inventions of Geneva, please visit:https://inventions-geneva.ch/en/home/.

About Technology Transfer Office, HKUThe Technology Transfer Office (TTO) manages the use of HKUs intellectual property assets by providing patenting, licensing and other commercialisation support to the Universitys researchers and inventors. Acting as the bridge linking HKU to society in the area of technology commercialisation, TTO helps industries and businesses to access HKUs powerhouse of knowledge, innovation and expertise through close collaboration. Website:http://www.tto.hku.hk.

For media enquiries, please contact:Communications and Public Affairs Office, HKUMs Melanie Wan (Email: melwkwan@hku.hk)Ms Jaymee Ng (Email:ngjaymee@hku.hk)Mr Kenneth Choi (Email:khkchoi@hku.hk)

Technology Transfer Office, HKUMs Joy Ma (Email: joy@tto.hku.hk)

The rest is here:
HKUs innovative research novelties excel at - EurekAlert

Biological Safety Testing Market to Reach $12.98 Billion by 2032, Driven by Rising Demand for Biologics and – EIN News

The global biological safety testing market size was USD 4.32 billion in 2022 and is expected to reach USD 12.98 billion in 2032, and register a CAGR of 13%.

The market's expansion is further supported by the rising need for innovative technologies for biological safety testing. Manufacturers are continuously developing new technologies to increase the sensitivity and accuracy of biological safety testing while also saving time and money. Strict regulatory requirements for biological safety testing established by agencies such as the FDA, EMA, and PMDA are also driving the demand for biological safety testing at all stages of drug development.

Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/download-free-sample/1412

Moreover, the market's growth is being fueled by increasing demand for cell and gene therapies as potential treatment options for various diseases. However, the high cost of biological safety testing due to the use of innovative technologies and strict regulatory requirements could impede revenue growth. Furthermore, a scarcity of qualified individuals in the field of biological safety testing could limit the market's growth to some extent.

Segments Covered in the Report

The biological safety testing market offers a range of products and services, including instruments, kits and reagents, and services. Instruments and equipment are widely used for conducting biological safety tests in laboratories. Kits and reagents are used to measure the presence of contaminants, toxins, and other agents in samples. Services include testing, validation, and consulting services for companies in the pharmaceutical, biotechnology, and medical device industries.

The market for biological safety testing is also segmented by test type, including endotoxin tests, sterility tests, cell line authentication and characterization tests, bioburden tests, adventitious agent detection tests, and others. Endotoxin tests are used to detect and quantify bacterial endotoxins, which can cause fever and sepsis in humans. Sterility tests are used to determine if a product or sample is free of microorganisms. Cell line authentication and characterization tests are used to ensure that cell lines used in research are accurate and free of contamination. Bioburden tests are used to measure the total number of viable microorganisms in a sample, and adventitious agent detection tests are used to detect the presence of viruses, bacteria, fungi, and other contaminants.

The biological safety testing market is also segmented by application, including blood and blood products, vaccines and therapeutics, gene therapy, tissue and tissue products, stem cell products, and others. Blood and blood products are tested to ensure that they are free of contaminants and diseases before being used for transfusions. Vaccines and therapeutics are tested to ensure that they are safe and effective before being approved for use in humans. Gene therapy products are tested to ensure that they are safe and effective and to monitor any adverse reactions. Tissue and tissue products are tested to ensure that they are free of diseases and contaminants before being used in transplantation procedures. Stem cell products are tested to ensure that they are safe and effective before being used in regenerative medicine.

Access Full Report Description with Research Methodology and Table of Contents @ https://www.reportsanddata.com/report-detail/biological-safety-testing-market

Strategic development:

Thermo Fisher Scientific announced in 2021 that it acquired PPD, Inc., a global contract research organization (CRO) that offers a wide range of drug development services, including biological safety testing. The acquisition aimed to enhance Thermo Fisher's offerings in the CRO market and strengthen its position in the biological safety testing market.

In the same year, Charles River Laboratories International, Inc. expanded its biologics testing capabilities by establishing a new laboratory in Shanghai, China. The new facility offers a complete range of biologics testing services, which includes biological safety testing.

In 2020, Merck KGaA disclosed the addition of a new laboratory in Carlsbad, California, which expanded its global BioReliance viral and gene therapy testing capabilities. The laboratory provides a comprehensive range of biological safety testing services for viral and gene therapy products.

Competitive Landscape:

The global biological safety testing market is projected to see substantial growth in the coming years as the demand for biologics and biosimilars continues to rise. The development of these complex molecules in the pharmaceutical and biotechnology sectors has created a pressing need for effective safety testing to ensure their efficacy and safety before they are released to the market. The biological safety testing market is relatively concentrated, with a few major players holding a significant share of the market.

Merck KGaA, Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Lonza Group AG, SGS SA, WuXi AppTec, Eurofins Scientific SE, Cytiva, bioMrieux SA, and Sartorius AG are among the key players included in the global biological safety testing market report. These companies offer a wide range of services in the biological safety testing market, including endotoxin tests, sterility tests, cell line authentication and characterization tests, bioburden tests, adventitious agent detection tests, and others.

To expand their offerings and strengthen their positions in the market, many of these companies have pursued mergers and acquisitions, as well as the opening of new testing facilities. For example, Thermo Fisher Scientific Inc. recently acquired PPD, Inc., a contract research organization that offers biological safety testing services, while Charles River Laboratories International, Inc. expanded its biologics testing capabilities with the opening of a new laboratory in Shanghai, China.

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1412

Overall, the biological safety testing market plays a crucial role in ensuring the safety and efficacy of pharmaceuticals, biologics, and medical devices. The demand for biological safety testing is driven by the growing need for advanced healthcare products and services, rising incidences of chronic diseases, and increasing investments in research and development.

Browse for more reports:

Botulinum Toxins Market - https://www.reportsanddata.com/report-detail/botulinum-toxins-market

Breast Ultrasound Market - https://www.reportsanddata.com/report-detail/breast-ultrasound-market

Cannabis Pharmaceuticals Market - https://www.reportsanddata.com/report-detail/cannabis-pharmaceuticals-market

Care Management Solution Market - https://www.reportsanddata.com/report-detail/care-management-solution-market

Cell Expansion Market - https://www.reportsanddata.com/report-detail/cell-expansion-market

Nikhil MorankarReports and Data+ 12127101370email us hereVisit us on social media:FacebookTwitterLinkedIn

The rest is here:
Biological Safety Testing Market to Reach $12.98 Billion by 2032, Driven by Rising Demand for Biologics and - EIN News

The Skin’s Secret Weapon: Researchers Uncover an Ancient … – SciTechDaily

A variety of cells (white) proliferate at the ragged edge of a five-day-old wound, including epidermal stem cells (basal layer of epithelium in green), which secrete IL24. Credit: Laboratory of Elaine Fuchs

The world can be a hazardous place, with various dangers lurking around us such as bacteria, viruses, accidents, and injuries. Our skin acts as the ultimate shield, providing a steadfast defense against these threats. It serves as the boundary between the internal and external environment and is the largest organ in the body, functioning nearly seamlessly to protect us.

Still, the skin is not immune to harm. It endures daily assaults and still tries to keep us safe by detecting and responding to these dangers. One method is the detection of pathogens, which activates the immune system. However, recent research conducted by Elaine Fuchs at Rockefeller University and published in the journal Cell, has uncovered a new protection mechanism that responds to injury signals in damaged tissue, such as low oxygen levels caused by blood vessel disruption and scab formation. This mechanism is activated without the need for an infection.

The study is the first to identify a damage response pathway that is distinct from but parallel to the classical pathway triggered by pathogens.

At the helm of the response is interleukin-24 (IL24), whose gene is induced in skin epithelial stem cells at the wound edge. Once unleashed, this secreted protein begins to marshal a variety of different cells to begin the complex process of healing.

IL24 is predominately made by the wound-edge epidermal stem cells, but many cells of the skinthe epithelial cells, the fibroblasts, and the endothelial cellsexpress the IL24 receptor and respond to the signal. IL24 becomes an orchestrator that coordinates tissue repair, says Fuchs, head of the Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development.

Scientists have long understood how the host responses protect our body from pathogen-induced threats: somatic cells recognize invading bacteria or viruses as foreign entities and induce a number of defense mechanisms with the help of signaling proteins such as type 1 interferons.

But how does the body respond to an injury that may or may not involve foreign invaders? If we cut a finger while slicing a cucumber, for example, we know it instantlytheres blood and pain. And yet how the detection of injury leads to healing is poorly understood on a molecular basis.

While type 1 interferons rely on the signaling factors STAT1 and STAT2 to regulate the defense against pathogens, previous research by the Fuchs lab had shown that a similar transcription factor known as STAT3 makes its appearance during wound repair. Siqi Liu, a co-first author in both studies, wanted to trace STAT3s pathway back to its origin.

IL24 stood out as a major upstream cytokine that induces STAT3 activation in the wounds.

In collaboration with Daniel Mucidas lab at Rockefeller, the researchers worked with mice under germ-free conditions and found that the wound-induced IL24 signaling cascade is independent of germs.

But what injury signals induced the cascade? Wounds often extend into the skin dermis, where capillaries and blood vessels are located.

We learned that the epidermal stem cells sense the hypoxic environment of the wound, says Yun Ha Hur, a research fellow in the lab and a co-first author on the paper.

When the blood vessels are severed and a scab forms, epidermal stem cells at the edge of the wound are starved of oxygen. This state of hypoxia is an alarm bell for cell health and induced a positive feedback loop involving transcription factors HIF1a and STAT3 to amplify IL24 production at the wound edge. The result was a coordinated effort by a variety of cell types expressing the IL24 receptor to repair the wound by replacing damaged epithelial cells, healing broken capillaries, and generating fibroblasts for new skin cells.

Collaborating with Craig Thompsons group at Memorial Sloan Kettering Cancer Center, the researchers showed that they could regulate Il24 gene expression by changing oxygen levels.

Once the researchers pinpointed the origin of the tissue-repair pathway in epidermal stem cells, they studied the wound repair process in mice that had been genetically modified to lack IL24 functionality. Without this key protein, the healing process was sluggish and delayed, taking days longer than in normal mice to completely restore the skin.

They speculate that IL24 might be involved in the injury response in other body organs featuring epithelial layers, which act as a protective sheath. In recent studies, elevated IL24 activity has been spotted in epithelial lung tissue of patients with severe COVID-19 and in colonic tissue in patients with ulcerative colitis, a chronic inflammatory bowel disease.

IL24 could be working as a cue to signal the need for injury repair in many organs, Hur says.

Our findings provide insights into an important tissue damage sensing and repair signaling pathway that is independent of infections, explains Fuchs.

An analysis with evolutionary biologist Qian Cong at UT Southwestern Medical Center revealed that IL24 and its receptors share close sequence and structure homology with the interferon family. Though they may not always be working in coordination at every moment, IL24 and interferons are evolutionarily related and bind to receptors sitting near each other on the surface of cells. The researchers suspect that these signaling molecules derive from a common molecular pathway dating far back in our past.

We think that hundreds of millions of years ago, this ancestor might have diverged into two pathwaysone being pathogen defense and the other being tissue injury, Liu says.

Perhaps the split occurred to cope with an explosion of pathogens and injuries that caused a sea of troubles for life on Earth.

Reference: A tissue injury sensing and repair pathway distinct from host pathogen defense by Siqi Liu, Yun Ha Hur, Xin Cai, Qian Cong, Yihao Yang, Chiwei Xu, Angelina M. Bilate, Kevin Andrew Uy Gonzales, S. Martina Parigi, Christopher J. Cowley, Brian Hurwitz, Ji-Dung Luo, Tiffany Tseng, Shiri Gur-Cohen, Megan Sribour, Tatiana Omelchenko, John Levorse, Hilda Amalia Pasolli, Craig B. Thompson, Daniel Mucida and Elaine Fuchs, 24 April 2023, Cell.DOI: 10.1016/j.cell.2023.03.031

Originally posted here:
The Skin's Secret Weapon: Researchers Uncover an Ancient ... - SciTechDaily

Global Breast Cancer Market Size Projected To Hit $70 Billion in … – StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Palm Beach, FL - May 5, 2023 FinancialNewsMedia.com News Commentary Breast cancer is the most commonly occurring disorder among the population majorly seen in females with rising disorder. It is a disorder that spreads the disease with increasing symptoms such as pain in the bones swelling of lymph nodes, breathing problems, and many more. Breast cancer development takes place with the presence of genes like Human Epidermal growth factor receptor 2 (HER2). Stimulation of cancer in the body with the presence of this protein extends the proliferation of the cells. Positive HER2 receptor patients having the most aggression in breast cancer than other types of breast cancer. Numerous treatments are available which are used to treat and eradicate the tumor and increase the target on HER2. Which enlarges the market of Breast cancer with an increasing number of patients every year with an increase in the recovery rate of breast cancer. A report from Precedence Research projects that the global breast cancer market size was estimated at USD 31.89 billion in 2022 and is projected to hit around USD 70.51 billion by 2030 with a registered CAGR of 10.43% during the forecast period 2022 to 2030. The report said: "Enhance research and development with increased new technologies and therapies developed in breast cancer which is prominently contributing to enhancing the market growth with increased demands from the medical sector for treating the patients with new treatments and medications. Government support with increasing providence for new developments in medications and increased efficiency and efficacy of the treatment and integration of newly developed medications in the medical sector." Active biotech and pharma companies in the markets this week include Oncolytics Biotech(R) Inc. (NASDAQ: ONCY) (TSX: ONC), Bristol Myers Squibb (NYSE: BMY), NANO-X IMAGING LTD (NASDAQ: NNOX), Soligenix, Inc. (NASDAQ: SNGX), Cardiff Oncology, Inc. (NASDAQ: CRDF).

Precedence Research said that key insights were: "By therapy, the targeted therapy segments involved the largest market; By cancer type, the hormone receptor segments extend the market share at the largest rate; By distribution channel, the hospital pharmacies segments developed their own pharmacies in the hospital with the highest market share; and By geography, The North American region holds the highest position in the market with increased market share. On the basis of geography, North America holds the highest position in the market with an increased market share in breast cancer. Advanced developed technologies in the market with an increased number of treatments available for treating breast cancer with an increasing number of patients helps to propel the market growth with increased government initiative in developing new drug developments and increased efficacy of the medications with increased results help to enhance the market growth."

Oncolytics Biotech(R) Inc. (NASDAQ: ONCY) (TSX: ONC) BREAKING NEWS: Oncolytics Biotech(R) Reports First Quarter 2023 Financial Results and Operational Highlights -

Oncolytics Biotech(R) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

"Our core programs in breast and pancreatic cancer are moving towards registrational studies with compelling clinical data and important milestones expected this year," said Dr. Matt Coffey, President and Chief Executive Officer. "The first of these milestones will come later this month when we report data from BRACELET-1, a randomized phase 2 trial expected to inform the design of a subsequent pivotal registrational study in HR+/HER2- metastatic breast cancer. Stakeholders across the breast cancer community have demonstrated a keen interest in this readout, which will add to a dataset that already includes statistically significant phase 2 results showing pelareorep's ability to drive a robust overall survival benefit in this indication. Notably, the BRACELET-1 abstract was selected for an oral presentation at the upcoming ASCO meeting, providing a highly prestigious venue to discuss the results with potential partners and the clinical community."

Dr. Coffey continued, "Looking into the second half of 2023, we expect to report updated results from GOBLET's first-line pancreatic cancer cohort and provide guidance on the optimal registration paths for our breast and pancreatic cancer programs. With these programs both targeting large markets with significant clinical unmet needs and supported by robust clinical proof-of-concept data, we believe confirming their paths towards approval will represent important value-creating events and substantially de-risk and maintain pelareorep's development pathway." CONTINUED... Read this full press release and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/

Other recent developments in the biotech industry of note include:

NANO-X IMAGING LTD (NASDAQ: NNOX) recently announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the multi-source Nanox.ARC, including the Nanox.CLOUD, its accompanying cloud-based infrastructure. Nanox.ARC is a stationary X-ray system intended to produce tomographic images of the human musculoskeletal system adjunctive to conventional radiography on adult patients. Representing a major advancement in X-ray technology, Nanox.ARC is a multi-source digital 3D tomosynthesis system that utilizes novel, cold cathode X-ray tubes, which the Company intends to offer using an innovative pay-per-scan business model.

The FDA cleared Nanox.ARC for use in professional healthcare ??facilities or ??radiological ??environments, such as ??hospitals, clinics, imaging ??centers, and ??other medical practices?? by trained radiographers, ??radiologists, and physicians, and has the potential to increase availability to medical imaging around the world, once approved by local regulatory authorities and deployed at scale.

Soligenix, Inc. (NASDAQ: SNGX) recently announced positive clinical results from a compatibility study evaluating HyBryte (synthetic hypericin sodium) in the treatment of cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device, which recently received 510(k) clearance from U.S. Food and Drug Administration (FDA). The open-label study (protocol HPN-CTCL-02) enrolled 9 patients to receive 8 weeks of HyBryte treatment of their cancerous lesions, with an assessment of treatment response conducted at week 10 using the Composite Assessment of Index Lesion Severity (CAILS) score. All subjects were enrolled by Brian Poligone, MD, PhD, at the Rochester Skin Lymphoma Medical Group.

We were excited for the opportunity to work with Soligenix and make HyBryte available to our patients, stated Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group, Fairport, NY, and Principal Investigator for the compatibility study and Leading Enrolling Investigator in the FLASH study. Since the completion of the Phase 3 FLASH study, I have had a number of patients asking about possible access to this promising therapy. Fortunately, we were chosen to conduct this study and the patients enthusiasm for the product was evident by their willingness to participate in the trial, allowing for its rapid completion. I look forward to continuing to work with Soligenix to further advance the HyBryte program so my patients can have this much needed treatment option available to them.

Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, recently announced that the first patient was dosed this month with its investigational drug onvansertib in its Phase 2 ONSEMBLE trial (NCT05593328). The trial is designed to demonstrate a clinically meaningful difference in response and onvansertibs contribution to standard of care (SoC) FOLFIRI/bevacizumab for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC).

We are excited to be underway with our ONSEMBLE trial that builds on the promising efficacy and tolerability results demonstrated in our phase 1b/2 trial in mCRC, said Fairooz Kabbinavar, MD, Chief Medical Officer of Cardiff Oncology. mCRC is a difficult-to-treat cancer and patients in the second line setting need novel therapeutic options to improve clinical outcomes. Based on our open-label phase 1b/2 trial, we believe the combination of onvansertib with FOLFIRI/bevacizumab could positively impact patients responses to treatment and the durability of the responses. Nearly half of our planned 40 sites in the US are open to enroll patients and weve seen great enthusiasm from participating investigators.

Bristol Myers Squibb (NYSE: BMY) recently announced that the European Commission (EC) has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. This approval covers all European Union (EU) member states.

The approval is based on results from the pivotal Phase 3 TRANSFORM trial in which Breyanzi demonstrated statistically significant and clinically meaningful improvements in the study's primary endpoint of event-free survival (EFS), and key secondary endpoints of complete responses (CR) and progression-free survival (PFS) compared to standard therapy (consisting of salvage immunochemotherapy followed by high-dose chemotherapy and hematopoietic stem cell transplant [HSCT]), along with a manageable and well-established safety profile.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMs market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech(R) Inc. by a non-affiliated third party.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as may, future, plan or planned, will or should, expected, anticipates, draft, eventually or projected. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companys annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [emailprotected] +1(561)325-8757

SOURCE Financialnewsmedia.com

The post Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030 appeared first on Financial News Media.

COMTEX_431764985/2692/2023-05-05T08:46:29

Read the original post:
Global Breast Cancer Market Size Projected To Hit $70 Billion in ... - StreetInsider.com

Childrens Hospital Los Angeles Researchers Uncover New Clues to Origins of the Most Common Pediatric Kidney Cancer – Newswise

Newswise While Wilms tumoralso known as nephroblastoma-- is rare, it is the most prevalent childhood kidney cancer. Researchers at Childrens Hospital Los Angeles have now pinpointed a disruption in early kidney progenitor cell development that can be linked to the formation of Wilms tumor.

In a study published in Advanced Science, researchers at the GOFARR Laboratory in Urology compared kidney progenitor cells from a tumor with precursor cells from a healthy kidney. Normally, these precursor cells mature into kidney cells, but when their early development is dysregulated, they behave like cancer stem cells.

While most children with Wilms tumor are successfully treated, current therapies are aggressive. A minority of these patients have unfavorable prognoses or relapses; for these children, there is no existing therapy. By achieving a more precise understanding of how Wilms tumors develop, our goal is to find new treatments for all types of Wilms tumor, says Laura Perin, PhD, Co-Director of the GOFARR laboratory and senior study co-author with Stefano Da Sacco, PhD, another researcher at the GOFARR Laboratory.

Pediatric Wilms tumor can be considered a developmental cancer, says Dr. Perin, who is also Associate Professor at the Keck School of Medicine of USC. The normal adult kidney lacks kidney precursor cells, as they are exhausted before birth. But in Wilms tumors, instead of giving rise to a functional kidney, these precursor cells persist and form the tumor mass.

The researchers characterized these Wilms tumor kidney precursor cells, finding that these cells can reproduce the original tumor. They are aggressive, theyre drug-resistant, they metastasize like cancer cells, and they are able to create the full tumor that we see in patients, says Astgik Petrosyan, PhD, researcher at the GOFARR Lab and first author of the study.

The kidney precursor cells that generate Wilms tumors also abnormally expressed ITG1 and ITG4, proteins that help cells communicate with their microenvironment. This abnormal attachment to their microenvironment favors the uncontrolled replication of these cells and guides the formation of the tumor mass, says Dr. Da Sacco.

"Our findings provide a more accurate understanding of the different stages of both normal and abnormal kidney development, says Dr. Perin. This can possibly help the diagnosis of Wilms tumor, leading to more effective treatments for these patients.

Other study co-authors include: Valentina Villania, PhD, of CHLA; Paola Aguiari, PhD, of CHLA and David Geffen School of Medicine at UCLA - VA Healthcare System; Matthew E. Thornton, MS, of the Keck School of Medicine of USC; Yizhou

Wang, PhD, and Alex Rajewski, PhD, of Cedars-Sinai Medical Center; Shengmei Zhou, MD, of CHLA, Paolo Cravedi, MD, PhD of the Icahn School of Medicine at Mount Sinai; Brendan H. Grubbs, MD, of the Keck School of Medicine of USC; Roger E. De Filippo, MD, Sargis Sedrakyan, PhD and Kevin V. Lemley, MD, PhD, of CHLA and the Keck School of Medicine at USC; and Marie Csete, MD, PhD of USC.

About Childrens Hospital Los Angeles

Childrens Hospital Los Angeles is at the forefront of pediatric medicine, offering acclaimed care to children from across the world, the country and the greater Southern California region. Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No. 1 pediatric hospital in the Pacific region and California, and among the top 10 in the nation on U.S. News & World Reports Honor Roll of Best Childrens Hospitals. Clinical expertise spans the pediatric care continuum for newborns to young adults, from everyday preventive medicine to the most advanced cases. Inclusive, kid- and family-friendly clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC, and proven discoveries reach patients faster through The Saban Research Institute of Childrens Hospital Los Angelesamong the top 10 childrens hospitals for National Institutes of Health funding. The hospital also is home to the largest pediatric residency training program at a freestanding childrens hospital in the western United States. To learn more, follow us onFacebook,Instagram,LinkedIn,YouTubeandTwitter, and visit our blog atCHLA.org/blog.

Read this article:
Childrens Hospital Los Angeles Researchers Uncover New Clues to Origins of the Most Common Pediatric Kidney Cancer - Newswise

Uncovering the transcriptional regulatory network involved in … – Nature.com

Haberlandt, G. in Plant Tissue Culture: 100 Years Since Gottlieb Haberlandt (eds Laimer, M. & Rcker, W.) 124 (Springer, 2003); https://doi.org/10.1007/978-3-7091-6040-4_1

Bidabadi, S. S. & Jain, S. M. Cellular, molecular, and physiological aspects of in vitro plant regeneration. Plants 9, 702 (2020).

Article CAS PubMed PubMed Central Google Scholar

Thorpe, T. A. History of plant tissue culture. Mol. Biotechnol. 37, 169180 (2007).

Article CAS PubMed Google Scholar

Radhakrishnan, D. et al. Shoot regeneration: a journey from acquisition of competence to completion. Curr. Opin. Plant Biol. 41, 2331 (2018).

Article CAS PubMed Google Scholar

Shin, J., Bae, S. & Seo, P. J. De novo shoot organogenesis during plant regeneration. J. Exp. Bot. 71, 6372 (2019).

Article Google Scholar

Hayta, S. et al. An efficient and reproducible Agrobacterium-mediated transformation method for hexaploid wheat (Triticum aestivum L.). Plant Methods 15, 121 (2019).

Article CAS PubMed PubMed Central Google Scholar

Ikeuchi, M. et al. Molecular mechanisms of plant regeneration. Annu. Rev. Plant Biol. 70, 377406 (2019).

Article CAS PubMed Google Scholar

Hu, B. et al. Divergent regeneration-competent cells adopt a common mechanism for callus initiation in angiosperms. Regeneration 4, 132139 (2017).

Article CAS PubMed PubMed Central Google Scholar

Atta, R. et al. Pluripotency of Arabidopsis xylem pericycle underlies shoot regeneration from root and hypocotyl explants grown in vitro. Plant J. 57, 626644 (2009).

Article CAS PubMed Google Scholar

Sugimoto, K., Jiao, Y. & Meyerowitz, E. M. Arabidopsis regeneration from multiple tissues occurs via a root development pathway. Dev. Cell 18, 463471 (2010).

Article CAS PubMed Google Scholar

Hu, X. & Xu, L. Transcription factors WOX11/12 directly activate WOX5/7 to promote root primordia initiation and organogenesis. Plant Physiol. 172, 23632373 (2016).

Article CAS PubMed PubMed Central Google Scholar

Liu, J. et al. The WOX11-LBD16 pathway promotes pluripotency acquisition in callus cells during de novo shoot regeneration in tissue culture. Plant Cell Physiol. 59, 734743 (2018).

Article PubMed Google Scholar

Liu, J. et al. WOX11 and 12 are involved in the first-step cell fate transition during de novo root organogenesis in Arabidopsis. Plant Cell 26, 10811093 (2014).

Article CAS PubMed PubMed Central Google Scholar

Gordon, S. P. et al. Pattern formation during de novo assembly of the Arabidopsis shoot meristem. Development 134, 35393548 (2007).

Article CAS PubMed Google Scholar

Meng, W. J. et al. Type-B ARABIDOPSIS RESPONSE REGULATORs specify the shoot stem cell niche by dual regulation of WUSCHEL. Plant Cell 29, 13571372 (2017).

Article CAS PubMed PubMed Central Google Scholar

Kareem, A. et al. PLETHORA genes control regeneration by a two-step mechanism. Curr. Biol. 25, 10171030 (2015).

Article CAS PubMed PubMed Central Google Scholar

Liu, X., Zhu, K. & Xiao, J. Recent advances in understanding of the epigenetic regulation of plant regeneration. aBIOTECH https://doi.org/10.1007/s42994-022-00093-2 (2023).

He, C., Chen, X., Huang, H. & Xu, L. Reprogramming of H3K27me3 is critical for acquisition of pluripotency from cultured Arabidopsis tissues. PLoS Genet. 8, e1002911 (2012).

Article CAS PubMed PubMed Central Google Scholar

Lee, K., Park, O.-S. & Seo, P. J. Arabidopsis ATXR2 deposits H3K36me3 at the promoters of LBD genes to facilitate cellular dedifferentiation. Sci. Signal. 10, eaan0316 (2017).

Article PubMed Google Scholar

Lee, K. et al. Arabidopsis ATXR2 represses de novo shoot organogenesis in the transition from callus to shoot formation. Cell Rep. 37, 109980 (2021).

Article CAS PubMed Google Scholar

Lee, K., Park, O.-S., Choi, C. Y. & Seo, P. J. ARABIDOPSIS TRITHORAX 4 facilitates shoot identity establishment during the plant regeneration process. Plant Cell Physiol. 60, 826834 (2019).

Article CAS PubMed Google Scholar

Liu, H., Zhang, H., Dong, Y. X., Hao, Y. J. & Zhang, X. S. DNA METHYLTRANSFERASE1-mediated shoot regeneration is regulated by cytokinin-induced cell cycle in Arabidopsis. New Phytol. 217, 219232 (2018).

Article CAS PubMed Google Scholar

Hiei, Y., Ishida, Y. & Komari, T. Progress of cereal transformation technology mediated by Agrobacterium tumefaciens. Front. Plant Sci. 5, 628 (2014).

Article PubMed PubMed Central Google Scholar

Ishida, Y., Tsunashima, M., Hiei, Y. & Komari, T. Wheat (Triticum aestivum L.) transformation using immature embryos. Methods Mol. Biol. 1223, 189198 (2015).

Article CAS PubMed Google Scholar

Zhang, W. et al. Regeneration capacity evaluation of some largely popularized wheat varieties in China. Acta Agron. Sin. 44, 208217 (2018).

Article Google Scholar

Wang, K., Liu, H., Du, L. & Ye, X. Generation of marker-free transgenic hexaploid wheat via an Agrobacterium-mediated co-transformation strategy in commercial Chinese wheat varieties. Plant Biotechnol. J. 15, 614623 (2017).

Article CAS PubMed Google Scholar

Lowe, K. et al. Morphogenic regulators Baby boom and Wuschel improve monocot transformation. Plant Cell 28, 19982015 (2016).

Article CAS PubMed PubMed Central Google Scholar

Suo, J. et al. Identification of regulatory factors promoting embryogenic callus formation in barley through transcriptome analysis. BMC Plant Biol. 21, 145 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, K. et al. The gene TaWOX5 overcomes genotype dependency in wheat genetic transformation. Nat. Plants 8, 110117 (2022).

Article PubMed Google Scholar

Debernardi, J. M. et al. A GRF-GIF chimeric protein improves the regeneration efficiency of transgenic plants. Nat. Biotechnol. 38, 12741279 (2020).

Article CAS PubMed PubMed Central Google Scholar

Qiu, F. et al. Transient expression of a TaGRF4-TaGIF1 complex stimulates wheat regeneration and improves genome editing. Sci. China Life Sci. 65, 731738 (2022).

Article CAS PubMed Google Scholar

Zhao, L. et al. Dynamic chromatin regulatory programs during embryogenesis of hexaploid wheat. Genome Biol. 24, 7 (2023).

Article CAS PubMed PubMed Central Google Scholar

Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 20, 207220 (2019).

Article CAS PubMed Google Scholar

Wang, M. et al. An atlas of wheat epigenetic regulatory elements reveals subgenome divergence in the regulation of development and stress responses. Plant Cell 33, 865881 (2021).

Article PubMed PubMed Central Google Scholar

Sarkar, A. K. et al. Conserved factors regulate signalling in Arabidopsis thaliana shoot and root stem cell organizers. Nature 446, 811814 (2007).

Article CAS PubMed Google Scholar

Yu, J., Liu, W., Liu, J., Qin, P. & Xu, L. Auxin control of root organogenesis from callus in tissue culture. Front. Plant Sci. 8, 1385 (2017).

Article PubMed PubMed Central Google Scholar

Della Rovere, F. et al. Auxin and cytokinin control formation of the quiescent centre in the adventitious root apex of Arabidopsis. Ann. Bot. 112, 13951407 (2013).

Article PubMed PubMed Central Google Scholar

Wu, L. Y. et al. Dynamic chromatin state profiling reveals regulatory roles of auxin and cytokinin in shoot regeneration. Dev. Cell 57, 526542 (2022).

Article CAS PubMed Google Scholar

Ikeuchi, M. et al. A gene regulatory network for cellular reprogramming in plant regeneration. Plant Cell Physiol. 59, 770782 (2018).

Article CAS PubMed Central Google Scholar

Shi, B. et al. Two-step regulation of a meristematic cell population acting in shoot branching in Arabidopsis. PLoS Genet. 12, e1006168 (2016).

Article PubMed PubMed Central Google Scholar

Hao, C. et al. Resequencing of 145 landmark cultivars reveals asymmetric sub-genome selection and strong founder genotype effects on wheat breeding in China. Mol. Plant 13, 17331751 (2020).

Article CAS PubMed Google Scholar

Bisht, A. et al. PAT1-type GRAS-domain proteins control regeneration by activating DOF3.4 to drive cell proliferation in Arabidopsis roots. Plant Cell https://doi.org/10.1093/plcell/koad028 (2023).

Fan, M., Xu, C., Xu, K. & Hu, Y. LATERAL ORGAN BOUNDARIES DOMAIN transcription factors direct callus formation in Arabidopsis regeneration. Cell Res. 22, 11691180 (2012).

Article CAS PubMed PubMed Central Google Scholar

Schulze, S., Schfer, B. N., Parizotto, E. A., Voinnet, O. & Theres, K. LOST MERISTEMS genes regulate cell differentiation of central zone descendants in Arabidopsis shoot meristems. Plant J. 64, 668678 (2010).

Article CAS PubMed Google Scholar

Wang, F. X. et al. Chromatin accessibility dynamics and a hierarchical transcriptional regulatory network structure for plant somatic embryogenesis. Dev. Cell 54, 742757 (2020).

Article CAS PubMed Google Scholar

Xu, M., Du, Q., Tian, C., Wang, Y. & Jiao, Y. Stochastic gene expression drives mesophyll protoplast regeneration. Sci. Adv. 7, eabg8466 (2021).

Article CAS PubMed PubMed Central Google Scholar

Bie, X. M. et al. Trichostatin A and sodium butyrate promotes plant regeneration in common wheat. Plant Signal. Behav. 15, 1820681 (2020).

Article PubMed PubMed Central Google Scholar

Jiang, F. et al. Trichostatin A increases embryo and green plant regeneration in wheat. Plant Cell Rep. 36, 17011706 (2017).

Article CAS PubMed Google Scholar

Zhao, N. et al. Systematic analysis of differential H3K27me3 and H3K4me3 deposition in callus and seedling reveals the epigenetic regulatory mechanisms involved in callus formation in rice. Front. Genet. 11, 766 (2020).

Article CAS PubMed PubMed Central Google Scholar

Daimon, Y., Takabe, K. & Tasaka, M. The CUP-SHAPED COTYLEDON genes promote adventitious shoot formation on calli. Plant Cell Physiol. 44, 113121 (2003).

Article CAS PubMed Google Scholar

Zhai, N. & Xu, L. Pluripotency acquisition in the middle cell layer of callus is required for organ regeneration. Nat. Plants 7, 14531460 (2021).

Article CAS PubMed Google Scholar

Liu, W. et al. Transcriptional landscapes of de novo root regeneration from detached Arabidopsis leaves revealed by time-lapse and single-cell RNA sequencing analyses. Plant Commun. 3, 100306 (2022).

The rest is here:
Uncovering the transcriptional regulatory network involved in ... - Nature.com